Galapagos NV has expanded its anti-infectives alliance with GlaxoSmithKline to include three more discovery targets. Galapagos will receive a payment of $2.7 million from GSK. In December 2007, the two companies initiated a program to discover and develop new antibacterial and antiviral drug candidates for GSK’s Infectious Diseases Centre of Excellence in Drug Discovery (ID CEDD). Galapagos is responsible for the discovery and development of natural product drug candidates through to c...